Publication:
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.

No Thumbnail Available

Date

2020-03-31

Authors

Ponce Aix, Santiago
Talbot, Denis
Govindan, Ramaswamy
Dols, Manuel Cobo
Postmus, Pieter E
Lewanski, Conrad
Bennouna, Jaafar
Fischer, Juergen R
Juan-Vidal, Oscar
Stewart, David J

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

Description

MeSH Terms

Adult
Aged
Aged, 80 and over
Albumins
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Female
Humans
Lung Neoplasms
Male
Middle Aged
Paclitaxel
Quality of Life
Retreatment
Treatment Outcome

DeCS Terms

CIE Terms

Keywords

EORTC QLQ-C30, EQ-5D-5L, durvalumab, lung cancer symptom scale, nab-paclitaxel, non-small cell lung cancer, quality of life

Citation